Literature DB >> 29623729

Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients.

Gerdien A Zeilmaker1, Paula Pokorna1,2,3, Paola Mian1, Enno D Wildschut1, Catherijne A J Knibbe4,5, Elke H J Krekels4, Karel Allegaert1,6, Dick Tibboel1.   

Abstract

INTRODUCTION: Adequate postoperative analgesia in pediatric patients in the intensive care unit (ICU) matters, since untreated pain is associated with negative outcomes. Compared to routine postoperative patients, children undergoing hypothermia (HT) or extracorporeal membrane oxygenation (ECMO), or recovering after cardiac surgery likely display non-maturational differences in pharmacokinetics (PK) and pharmacodynamics (PD). These differences warrant additional dosing recommendations to optimize pain treatment. Areas covered: Specific populations within the ICU will be discussed with respect to expected variations in PK and PD for various analgesics. We hereby move beyond maturational changes and focus on why PK/PD may be different in children undergoing HT, ECMO or cardiac surgery. We provide a stepwise manner to develop PK-based dosing regimens using population PK approaches in these populations. Expert opinion: A one-dose to size-fits-all for analgesia is suboptimal, but for several commonly used analgesics the impact of HT, ECMO or cardiac surgery on average PK parameters in children is not yet sufficiently known. Parameters considering both maturational and non-maturational covariates are important to develop population PK-based dosing advices as part of a strategy to optimize pain treatment.

Entities:  

Keywords:  ECMO; Pediatric; cardiac surgery; hypothermia; intensive care; pharmacodynamics; pharmacokinetics; population PK; post-operative

Mesh:

Substances:

Year:  2018        PMID: 29623729     DOI: 10.1080/17425255.2018.1461836

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  6 in total

Review 1.  The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review.

Authors:  Thomas K Wiersma; Marijn C Visschedijk; Nanne K de Boer; Marjolijn N Lub-de Hooge; Jelmer R Prins; Daan J Touw; Paola Mian
Journal:  Pharmaceutics       Date:  2022-06-11       Impact factor: 6.525

Review 2.  Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy.

Authors:  Joshua C Euteneuer; Suyog Kamatkar; Tsuyoshi Fukuda; Alexander A Vinks; Henry T Akinbi
Journal:  J Clin Pharmacol       Date:  2018-09-11       Impact factor: 3.126

Review 3.  Paracetamol in Older People: Towards Evidence-Based Dosing?

Authors:  Paola Mian; Karel Allegaert; Isabel Spriet; Dick Tibboel; Mirko Petrovic
Journal:  Drugs Aging       Date:  2018-07       Impact factor: 3.923

4.  Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass.

Authors:  P Mian; A J Valkenburg; K Allegaert; B C P Koch; C V Breatnach; C A J Knibbe; D Tibboel; E H J Krekels
Journal:  J Clin Pharmacol       Date:  2019-01-11       Impact factor: 3.126

5.  Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia.

Authors:  Laurent M A Favié; Floris Groenendaal; Marcel P H van den Broek; Carin M A Rademaker; Timo R de Haan; Henrica L M van Straaten; Peter H Dijk; Arno van Heijst; Jeroen Dudink; Koen P Dijkman; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Johanna H van der Lee; Debbie H G M Nuytemans; Frank van Bel; Toine C G Egberts; Alwin D R Huitema
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

Review 6.  A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.

Authors:  Anne Smits; Pieter Annaert; Steven Van Cruchten; Karel Allegaert
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.